Using Stockholm3 biomarker reduces unnecessary MRIs in patients on active surveillance. Read more 👇 prostate.uroonco.uroweb.org/publication/in… #prostatecancer #GUcancers #oncourology Tobias Nordström Hari Vigneswaran, MD Karolinska Institutet Anna Lantz Roderick van den Bergh

Thx to our team and our amazing fellow- Dr. Vinayak Wagaskar for taking a lead.

Our results from Mount Sinai; Social disparities significantly effects Covid outcomes. Social Determinants Predict Outcomes in Data From a Multi-Ethnic Cohort of 20,899 Patients Investigated for COVID-19 frontiersin.org/article/10.338…

Anna Lantz prostatacancerforbundet.se/forskning/aktu…

Baris Turkbey MD Andrei Purysko Felipe de Galiza Ivo Schoots Anwar Padhani Hold your horses: meta-analyses are of limited values without access to all datasets #DEVILisINdetail Our suggestion -> #PROMODstudy Great team work with Ugo_Falagario @albertoma90 and a long list of outstanding collaborators 👏 sciencedirect.com/science/articl… euoncology.europeanurology.com/article/S2588-…

Robot versus open #prostatectomy in the LAPPRO trial, continence and oncological outcomes per risk category. Read more 👇 prostate.uroonco.uroweb.org/publication/ur… #prostatecancer Anna Lantz Olof Akre Roderick van den Bergh

Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up buff.ly/3AjHHMa Anna Lantz Olof Akre Eva Angenete Anders Bjartell Stefan Carlsson

Anna Lantz en av ambassadörerna för Mustaschkampen 2021 nyheter.ki.se/anna-lantz-en-…

Articles in Press: Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings buff.ly/32xH7ff Anna Lantz Zach Dovey @albertoma90 Luigi Cormio Ash Tewari, MD

5-ARIs Do Not Increase Prostate Cancer Mortality renalandurologynews.com/home/conferenc…

Very happy to share our results on the association of 5ARI and risk for prostate cancer mortality concluding the 5ARI’s are safe to prescribe in terms of risk for prostate cancer death

News: A Swedish population-based study has found no increased risk for prostate cancer mortality with the use of 5α-reductase inhibitors. Reported by Lars Björnebo, Tobias Nordström Thorgerdur Palsdottir Anna Lantz & Karolinska Institutet team in JAMA Oncology UroUpdate bit.ly/3a1QYjW

LAPPRO data: Lymph swelling after RALP was 14% among men who had undergone lymph node dissection compared with 3.0% among men who had not bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

More evidence that taking 5ARIs for BPH is associated with a reduced risk of dying from prostate cancer. jamanetwork.com/journals/jamao…

Artificial urinary sphincter decreased incontinence from 500 to 7 g in men after prostatectomy! Something for robotic surgeons to keep in mind and refer potential candidates to neurourologists. Honored to be in examination board of Christine Reus thesis pubmed.ncbi.nlm.nih.gov/34082480/

Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists buff.ly/3N7vRdu Zach Dovey Yasmine Gharib Dimple Chakravarty Anna Lantz Ash Tewari, MD #COVID19 #prostatecancer #guidelines #urologists #openaccess #openscience

Risk of Recurrent Disease 6 Years After Open or Robotic-assisted Radical Prostatectomy in the Prospective Controlled Trial LAPPRO buff.ly/39WAnOP Olof Akre @DavidBo28287340 Sigrid Carlsson Stefan Carlsson Anna Lantz Stavros Tyritzis MD, PhD, FEBU, FACS Anders Bjartell #openscience #OpenAccess

The recruitment of Prostate Cancer IRE Study, PRIS, has started at Karolinska, evaluating and implementing focal therapy in localized intermediate risk prostate cancer comparing to conventional therapies #prostatecancer #focaltherapy #ire #karolinska

linkedin.com/posts/anna-lan…

Best of #EAU24 abstracts includes Organized Prostate Testing (OPT) initiatives in Sweden showing high compliance with screening and reduction in unnecessary biopsies. Congratulations, team! Anna Lantz Anders Bjartell Olof Akre Stefan Carlsson Tobias Nordström O Bratt R Godtman